About This Guide
This guide provides supplementary information for the Letermovir Dose Calculator. It details the tool’s outputs, usage instructions, and provides a clinical overview of letermovir (PREVYMIS®) dosing for cytomegalovirus (CMV) prophylaxis in adult allogeneic hematopoietic stem cell transplant (HSCT) recipients. Always use this information in conjunction with clinical judgment and official prescribing information.
Outputs Explained
The calculator provides the following key outputs based on the patient data entered:
- Recommended Dose: The calculated letermovir dose in milligrams (mg) for once-daily administration.
- Route of Administration: Displays the selected route (Oral or IV).
- Calculated Creatinine Clearance (CrCl): An estimated CrCl value using the Cockcroft-Gault equation, which helps assess renal function.
- Clinical Rationale & Notes: Important context, such as the reason for a dose adjustment (e.g., cyclosporine co-administration) or safety alerts related to renal function and IV administration.
How to Use the Calculator
- Enter Patient Demographics: Input the patient’s age (years), actual body weight (kg), and biological sex. These are required for the CrCl calculation.
- Input Serum Creatinine: Enter the patient’s most recent serum creatinine (SCr) value. Select the correct unit (mg/dL or µmol/L) to ensure accurate conversion and calculation.
- Select Route: Choose the intended route of administration, either Oral (PO) or Intravenous (IV).
- Indicate Cyclosporine Use: Specify whether the patient is concurrently taking cyclosporine. This is a critical factor for dose adjustment.
- Calculate: Click the “Calculate Dose” button to view the recommendation.
Dosing Overview
Letermovir dosing is primarily dependent on the co-administration of cyclosporine, a potent inhibitor of OATP1B1/3 transporters that significantly increases letermovir exposure.
| Patient Condition | Route | Recommended Letermovir Dose |
|---|---|---|
| Without Cyclosporine Co-administration | Oral (PO) or Intravenous (IV) | 480 mg once daily |
| With Cyclosporine Co-administration | Oral (PO) or Intravenous (IV) | 240 mg once daily |
Switching Between Formulations
Letermovir tablets and injection for intravenous infusion can be used interchangeably without a loading dose. Patients may be switched between IV and oral administration at the discretion of the physician. The dose remains the same regardless of the formulation (e.g., a patient on 480 mg IV can be switched to 480 mg PO).
Missed Dose Instructions
If a dose of letermovir is missed, the patient should be instructed to take it as soon as they remember. However, if it is less than 8 hours until the next scheduled dose, they should skip the missed dose and resume the normal dosing schedule. Patients should not take two doses at the same time to make up for a missed dose.
Safety Alerts
Renal Impairment & IV Administration
IV Formulation Excipient: The intravenous formulation of letermovir contains an excipient, hydroxypropyl betadex. In patients with a creatinine clearance (CrCl) less than 50 mL/min, this excipient can accumulate. Clinical consequences of this accumulation are unknown, but close monitoring of renal function (e.g., serum creatinine) is recommended for these patients. Consider switching to oral letermovir therapy if clinically appropriate.
Key Drug Interactions
Letermovir is involved in numerous significant drug-drug interactions. Always consult a comprehensive interaction database and the full prescribing information. Key interactions include:
- Contraindicated Drugs: Do not co-administer with pimozide or ergot alkaloids due to risk of serious adverse events.
- Cyclosporine: As noted, requires a dose reduction of letermovir to 240 mg daily.
- Rifampin: Co-administration with rifampin is not recommended as it may significantly decrease letermovir concentrations and lead to a loss of efficacy.
Frequently Asked Questions
Why is the dose adjusted for cyclosporine but not for tacrolimus or sirolimus?
Cyclosporine is a potent inhibitor of OATP1B1/3 transporters, which are crucial for letermovir’s metabolism. This inhibition causes a significant increase in letermovir plasma concentrations, necessitating a dose reduction. Tacrolimus and sirolimus do not inhibit these transporters to the same extent, so no dose adjustment for letermovir is required when co-administered.
What is CrCl and why does the calculator show it?
CrCl stands for Creatinine Clearance, an estimate of kidney function. The calculator uses the Cockcroft-Gault formula to estimate CrCl because it’s relevant for the specific warning regarding the IV letermovir formulation. The excipient in the IV solution can accumulate in patients with CrCl < 50 mL/min, so calculating this value is an important safety check.
Is a dose adjustment needed for low or high body weight?
No, the recommended letermovir dose (480 mg or 240 mg with cyclosporine) is a fixed dose and does not require adjustment based on body weight. Weight is included in the calculator solely for the purpose of estimating CrCl.
Can this calculator be used for children or non-HSCT patients?
No. This calculator is specifically designed for adult allogeneic HSCT recipients, which is the FDA-approved indication for letermovir. The safety and efficacy of letermovir have not been established in pediatric patients.
What about patients with hepatic impairment?
No dose adjustment of letermovir is required for patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Letermovir has not been studied in patients with severe (Child-Pugh Class C) hepatic impairment.
What happens if I enter serum creatinine in µmol/L?
The calculator is equipped with a unit toggle. If you enter a value while “µmol/L” is selected, it will automatically convert it to mg/dL (the standard unit for the Cockcroft-Gault equation) before calculating the CrCl. The output will display the original value and unit you entered for clarity.
What is the typical duration of letermovir prophylaxis?
In clinical trials, letermovir was typically started after HSCT (between Day 0 and Day 28) and continued through Day 100 post-transplantation. The duration of therapy should be determined by the treating physician based on the patient’s clinical status and risk for CMV infection.
What are the most common side effects of letermovir?
The most common adverse reactions reported in clinical trials (occurring in at least 10% of patients) include nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, and abdominal pain.
References
- PREVYMIS® (letermovir) tablets and injection prescribing information. Merck & Co., Inc., Rahway, NJ, USA. View PDF on FDA.gov
- U.S. Food and Drug Administration. Drugs@FDA: PREVYMIS (letermovir). Access FDA Database
- Marty FM, Ljungman P, Chemaly RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017;377(25):2433-2444. View on NEJM.org
- European Medicines Agency. Prevymis (letermovir) Summary of Product Characteristics (SmPC). View on EMA.europa.eu
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com